{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:34:50Z","timestamp":1791909290511,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We investigated the incidence of invasive fungal infections (IFIs) and other infectious complications in patients receiving venetoclax and hypomethylating agent therapy for acute myeloid leukaemia (AML). This retrospective, multicentre cohort study included adult patients with AML who received at least one cycle of venetoclax and either azacitidine or decitabine between January 2016 and August 2020. The primary outcome was the incidence of probable or confirmed IFI. Secondary outcomes included antifungal prophylaxis prescribing patterns, incidence of bacterial infections, and incidence of neutropenic fever hospital admissions. Among 235 patients, the incidence of probable or confirmed IFI was 5.1%. IFI incidence did not differ significantly according to age, antifungal prophylaxis use, or disease status. In the subgroup of patients with probable or confirmed IFIs, six (50%) were receiving antifungal prophylaxis at the time of infection. The overall incidence of developing at least one bacterial infection was 33.6% and 127 (54%) patients had at least one hospital admission for febrile neutropenia. This study demonstrated an overall low risk of developing probable or confirmed IFI as well as a notable percentage of documented bacterial infections and hospital admissions due to neutropenic fever.<\/jats:p>","DOI":"10.1111\/bjh.18051","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:08:35Z","timestamp":1645067315000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent"],"prefix":"10.1111","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-7824","authenticated-orcid":false,"given":"Sandy","family":"On","sequence":"first","affiliation":[{"name":"Department of Pharmacy Stanford Health Care  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn G.","family":"Rath","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services University of California, San Francisco Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California, San Diego Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California, Los Angeles Health  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Stanford Health Care  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Stanford Health Care  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Alegria","sequence":"additional","affiliation":[{"name":"Department of Quality, Patient Safety and Effectiveness Stanford Health Care  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services University of California, San Francisco Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisela","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services University of California, San Francisco Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California, Los Angeles Health  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Phun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California, Los Angeles Health  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy &amp; Pharmaceutical Sciences University of California, San Diego  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[{"name":"Division of Hematology Stanford Cancer Institute, Stanford University  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of California, San Francisco Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of California, San Francisco Health  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Blood &amp; Marrow Transplant, Department of Medicine University of California, San Diego Health  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-5991","authenticated-orcid":false,"given":"Randy A.","family":"Taplitz","sequence":"additional","affiliation":[{"name":"Department of Medicine City of Hope Medical Center  Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of California Los Angeles Medical Center  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Wen","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy &amp; Pharmaceutical Sciences University of California, San Diego  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila M.","family":"Saunders","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy &amp; Pharmaceutical Sciences University of California, San Diego  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Food and Drug Administration. FDA approves venetoclax in combination for AML in adults. Updated 14 December 2018.https:\/\/www.fda.gov\/drugs\/fda\u2010approves\u2010venetoclax\u2010combination\u2010aml\u2010adults."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_7_1","first-page":"4043","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss I","year":"2019","journal-title":"Am J Hematol"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.003"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.858"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_11_14_1","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia. (Version 3.2020).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"e_1_2_11_15_1","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer\u2010related infections. (Version 2.2020).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_2_11_18_1","volume-title":"Statistics in Epidemiology: Methods, Techniques, and Applications","author":"Sahai H","year":"1996"},{"key":"e_1_2_11_19_1","volume-title":"Modern Epidemiology","author":"Hanley H","year":"1986"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2646"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.08.013"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25808"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23368"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12500"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:42:33Z","timestamp":1692967353000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/bjh.18051"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18051","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"2021-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}